Sponsor content
299 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryElahere (mirvetuximab soravtansine) has been approved to treat adults with folate receptor-alpha (FRα) positive cancer of the ovary, fallopian tubes, or peritoneum who have stopped responding to platinum based chemotherapy and who have had one to 3 chemotherapy treatments before.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ELAHERE mirvetuximab soravtansine 100 mg/20 mL concentrate solution for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Abbvie Pty Ltd - Tube, feeding, gastrostomy.
-
Jan-2026Prescription medicine evaluationActive ingredient: upadacitinib hemihydrate.
-
Jan-2026Prescription medicine evaluationActive ingredient: trenibotulinumtoxinE.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Abbvie Pty Ltd - AbbVie ENFIT J - Gastrojejunostomy tube.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Abbvie Pty Ltd - ENFit/ENFit linear connector.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Abbvie Pty Ltd - ENFit small-bore multichannel connector.
-
-
Dec-2025Prescription medicine evaluationActive ingredient: upadacitinib hemihydrate.